Last reviewed · How we verify

HPV GSK 580299 vaccine

GlaxoSmithKline · Phase 3 active Biologic

HPV GSK 580299 vaccine is a Recombinant protein vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Prevention of human papillomavirus infection and HPV-associated cervical cancer, Prevention of other HPV-related cancers (anal, oropharyngeal, genital).

This vaccine stimulates the immune system to recognize and attack human papillomavirus (HPV)-infected cells by inducing antibodies and T-cell responses against HPV antigens.

This vaccine stimulates the immune system to recognize and attack human papillomavirus (HPV)-infected cells by inducing antibodies and T-cell responses against HPV antigens. Used for Prevention of human papillomavirus infection and HPV-associated cervical cancer, Prevention of other HPV-related cancers (anal, oropharyngeal, genital).

At a glance

Generic nameHPV GSK 580299 vaccine
SponsorGlaxoSmithKline
Drug classRecombinant protein vaccine
TargetHuman papillomavirus (HPV) L1 capsid protein
ModalityBiologic
Therapeutic areaOncology / Immunology
PhasePhase 3

Mechanism of action

HPV GSK 580299 is a prophylactic vaccine designed to prevent infection by human papillomavirus types associated with cervical cancer and other HPV-related malignancies. The vaccine contains recombinant HPV L1 capsid proteins or similar immunogenic components that trigger both humoral and cellular immune responses. By priming the immune system before natural HPV exposure, the vaccine prevents viral infection and the subsequent development of HPV-associated cancers.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about HPV GSK 580299 vaccine

What is HPV GSK 580299 vaccine?

HPV GSK 580299 vaccine is a Recombinant protein vaccine drug developed by GlaxoSmithKline, indicated for Prevention of human papillomavirus infection and HPV-associated cervical cancer, Prevention of other HPV-related cancers (anal, oropharyngeal, genital).

How does HPV GSK 580299 vaccine work?

This vaccine stimulates the immune system to recognize and attack human papillomavirus (HPV)-infected cells by inducing antibodies and T-cell responses against HPV antigens.

What is HPV GSK 580299 vaccine used for?

HPV GSK 580299 vaccine is indicated for Prevention of human papillomavirus infection and HPV-associated cervical cancer, Prevention of other HPV-related cancers (anal, oropharyngeal, genital).

Who makes HPV GSK 580299 vaccine?

HPV GSK 580299 vaccine is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

What drug class is HPV GSK 580299 vaccine in?

HPV GSK 580299 vaccine belongs to the Recombinant protein vaccine class. See all Recombinant protein vaccine drugs at /class/recombinant-protein-vaccine.

What development phase is HPV GSK 580299 vaccine in?

HPV GSK 580299 vaccine is in Phase 3.

What are the side effects of HPV GSK 580299 vaccine?

Common side effects of HPV GSK 580299 vaccine include Injection site pain or erythema, Fever, Myalgia, Headache.

What does HPV GSK 580299 vaccine target?

HPV GSK 580299 vaccine targets Human papillomavirus (HPV) L1 capsid protein and is a Recombinant protein vaccine.

Related